IFNG and lung carcinoma: However, we could not observe a further increase in PD-L1 levels in cisplatin-resistant lung cancer cells upon IFNγ treatment, probably due to the fact that PD-L1 levels in cisplatin-resistant lung cancer cells were high or the signaling pathways responsible for the up-regulation of PD-L1 were already highly activated in these cells.